Indivior Plc (INDV) Stock Price, Quote & News

Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorp...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 804 379 1090

Website: www.indivior.com

Address:

10710 Midlothian Turnpike, Suite 125, North Chesterfield, United States

Iightning Dec. 4 at 5:27 AM

1ightning® Premium Options Alert (Actionable) Ticker: $INDV Contract: Dec 19 $35C Entry: 0.85 Exit: 1.18 Return: +38.47% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 1 at 11:41 PM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $INDV **Contract:** Dec 19 $35C **Entry:** 0.85 **Exit:** 1.65 **Return:** **+93.76% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Iightning Nov. 26 at 2:30 AM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $0.88 Exit: $1.39 | Profit: 58.89% ROI | https://1ightning.com

0 · Reply

Night_Owl_Biotech Nov. 25 at 6:15 PM

The XBI is up 73% since hitting its low on 4/8/2025. Attached is a list of the % change in share price for all commercial-stage bio (oncology & non-oncology) since their 4/8/25 close. SCOPE: Market caps over $100MM 11 of 35 commercial-stage oncology focused bios beat the XBI during this time. In non-oncology 35 of 90 have done so. FDA approval dates are provided if you want to exclude NUVB was not technically commercial-stage on 4/8/25 but its on our list. $ADCT & $RIGL were otherwise the top performing stocks in this peer group. $ARWR $INDV & $EYPT have been the best performing stocks in non-oncology. This is for entertainment purposes only. This is not investment advice

1 · Reply

Iightning Nov. 25 at 12:35 PM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $0.88 Exit: $1.39 | Profit: 58.89% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 1:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $0.88 Exit: $1.39 | Profit: 58.89% ROI | https://1ightning.com

0 · Reply

BEATOFtheMARKET Nov. 22 at 9:11 PM

$INDB $INDV $INFU $INFY

0 · Reply

Iightning Nov. 21 at 10:47 PM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $1.01 Exit: $1.36 | Profit: 34.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 2:04 AM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $1.01 Exit: $1.36 | Profit: 34.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 11:28 PM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $1.01 Exit: $1.36 | Profit: 34.61% ROI | https://1ightning.com

0 · Reply

Indivior Concludes Legacy U.S. Department of Justice Matter

Nov 19, 2025, 9:21 AM EST - 15 days ago

Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 4 weeks ago

Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

Oct 30, 2025, 3:56 PM EDT - 4 weeks ago

Indivior PLC (INDV) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 2:18 PM EDT - 4 weeks ago

Here's Why Indivior Stock Soared 15% Today

Oct 30, 2025, 7:00 AM EDT - 5 weeks ago

Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

Oct 28, 2025, 10:00 AM EDT - 5 weeks ago

Indivior to Participate in the Stifel 2025 Healthcare Conference

Oct 16, 2025, 4:04 PM EDT - 6 weeks ago

Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

Oct 15, 2025, 8:00 AM EDT - 7 weeks ago

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

Oct 1, 2025, 9:35 AM EDT - 2 months ago

UK's Indivior to re-domicile to US after listing move

Oct 1, 2025, 8:00 AM EDT - 2 months ago

Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

Sep 8, 2025, 11:44 AM EDT - 3 months ago

Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 20, 2025, 12:00 PM EDT - 3 months ago

Indivior to Participate in Upcoming Investor Events

Aug 5, 2025, 5:39 PM EDT - 4 months ago

Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Aug 1, 2025, 5:22 AM EDT - 4 months ago

Indivior PLC (INDV) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 4:12 AM EDT - 4 months ago

Indivior (INDV) Q2 EPS Jumps 104%

Jul 31, 2025, 7:00 AM EDT - 4 months ago

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Jul 25, 2025, 2:00 AM EDT - 4 months ago

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Jul 23, 2025, 8:00 AM EDT - 4 months ago

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Jul 17, 2025, 9:00 AM EDT - 5 months ago

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

Jul 8, 2025, 8:00 AM EDT - 5 months ago

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

Jun 30, 2025, 7:00 AM EDT - 5 months ago

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

Jun 24, 2025, 4:12 PM EDT - 5 months ago

Indivior Appoints Tony Kingsley to the Board of Directors

Jun 19, 2025, 9:00 AM EDT - 6 months ago

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Jun 2, 2025, 2:33 AM EDT - 6 months ago

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Jun 2, 2025, 2:00 AM EDT - 6 months ago

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

May 27, 2025, 8:30 AM EDT - 6 months ago

Indivior Announces Patrick Barry as Chief Commercial Officer

May 1, 2025, 10:27 AM EDT - 7 months ago

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

Apr 28, 2025, 12:12 PM EDT - 7 months ago

Indivior: Trying To Break Addiction

Apr 24, 2025, 10:45 AM EDT - 8 months ago

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Apr 24, 2025, 2:00 AM EDT - 8 months ago

Indivior Announces Q1 2025 Financial Results

Mar 4, 2025, 8:40 AM EST - 9 months ago

Indivior Announces Further Changes to Board of Directors

Feb 27, 2025, 2:48 AM EST - 10 months ago

UK's Indivior appoints Joe Ciaffoni as CEO

Feb 27, 2025, 2:00 AM EST - 10 months ago

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Feb 24, 2025, 2:00 AM EST - 10 months ago

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Feb 20, 2025, 2:26 PM EST - 10 months ago

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:13 PM EST - 10 months ago

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Feb 20, 2025, 2:55 AM EST - 10 months ago

UK's Indivior forecasts 17% decline in 2025 revenue

Feb 20, 2025, 2:00 AM EST - 10 months ago

Indivior Announces FY and Q4 2024 Financial Results

Feb 12, 2025, 2:00 AM EST - 10 months ago

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Nov 19, 2024, 12:52 PM EST - 1 year ago

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Nov 7, 2024, 2:24 PM EST - 1 year ago

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Oct 30, 2024, 12:30 PM EDT - 1 year ago

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Oct 24, 2024, 2:02 PM EDT - 1 year ago

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 2:00 AM EDT - 1 year ago

Indivior Announces Q3 2024 Financial Results

Oct 13, 2024, 10:00 AM EDT - 1 year ago

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Oct 10, 2024, 7:33 AM EDT - 1 year ago

British drugmaker Indivior cuts 2024 revenue forecast, shares fall

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Oct 7, 2024, 11:30 AM EDT - 1 year ago

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Iightning Dec. 4 at 5:27 AM

1ightning® Premium Options Alert (Actionable) Ticker: $INDV Contract: Dec 19 $35C Entry: 0.85 Exit: 1.18 Return: +38.47% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 1 at 11:41 PM

0 · Reply

Iightning Nov. 26 at 2:30 AM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $0.88 Exit: $1.39 | Profit: 58.89% ROI | https://1ightning.com

0 · Reply

Night_Owl_Biotech Nov. 25 at 6:15 PM

1 · Reply

Iightning Nov. 25 at 12:35 PM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $0.88 Exit: $1.39 | Profit: 58.89% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 1:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $0.88 Exit: $1.39 | Profit: 58.89% ROI | https://1ightning.com

0 · Reply

BEATOFtheMARKET Nov. 22 at 9:11 PM

$INDB $INDV $INFU $INFY

0 · Reply

Iightning Nov. 21 at 10:47 PM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $1.01 Exit: $1.36 | Profit: 34.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 2:04 AM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $1.01 Exit: $1.36 | Profit: 34.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 11:28 PM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $1.01 Exit: $1.36 | Profit: 34.61% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 7:44 AM

1ightning® Options Trade Alert (Actionable) | Buy $INDV Dec 19 $35 Call | Enter: $1.01 Exit: $1.36 | Profit: 34.61% ROI | https://1ightning.com

0 · Reply

_o_0 Nov. 18 at 3:03 PM

$INDV moving up in the world ha ☺️ yay

0 · Reply

danaos Nov. 18 at 12:49 AM

$INDV Overweight

0 · Reply

BEATOFtheMARKET Nov. 17 at 12:48 AM

$ILMN $IMO $INBX $INDV $INNV

0 · Reply

MichaelKTrades Nov. 12 at 3:30 PM

$INDV Big gap up from multi week base, pullback to rising 10D moving average.

0 · Reply

TalkMarkets Nov. 6 at 10:47 PM

3 Top Ranked #Stocks That Are The Best Of The Best $TRV $OPFI $INDV https://talkmarkets.com/content/us-markets/3-top-ranked-stocks-that-are-the-best-of-the-best?post=534531

0 · Reply

BioTechHealthX Nov. 6 at 6:05 PM

$INDV Indivior boosts full-year outlook following strong execution in OUD platform; can INDV double? Click here to know more! https://biotechhealthx.com/biotech-news/why-indivior-indv-just-raised-2025-revenue-guidance-to-1-18-1-22b/

0 · Reply

RunnerSignals Nov. 1 at 11:59 AM

$CAH $COIN $FORM $GSAT $INDV surged yesterday hitting new highs 🚀 Friday momentum was strong, and charts were buzzing! https://stocksrunner.com/news/2025-11-01-daily-market-pulse-advanced-technical-analysis-stock-trading-strategies

0 · Reply

SlatsMcSlappy Oct. 30 at 9:37 PM

$INDV .72A vs .38E 3Q25, .54 3Q24 Revenues were 21% over est Raised revenue and earnings guidance

0 · Reply

howardlindzon Oct. 30 at 5:37 PM

$INDV the ozempic of opiodes still working

0 · Reply

howardlindzon Oct. 30 at 5:36 PM

$INDV shoulda coulda

1 · Reply

_o_0 Oct. 30 at 3:08 PM

$INDV ha ☺️ ⌚

0 · Reply

Market Cap	4.69B
Revenue (ttm)	1.19B
Net Income (ttm)	2.00M
EPS (ttm)	N/A
PE Ratio	17.14
Forward PE	15.54
Profit Margin	0.17%
Debt to Equity Ratio	-1.56

Volume	1,695,600
Avg Vol	1,952,400
Day's Range	N/A - N/A
Shares Out	137.88M
Stochastic %K	82%
Beta	0.74
Analysts	Strong Sell
Price Target	$37.00